Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-MR Imaging of NPR-C in Carotid Atherosclerosis With 64Cu-NODAGA-CANF
NCT07800481Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-NODAGA-CANF in atherosclerosis, sponsored by Washington University School of Medicine. Primary endpoints: Organ radiation dose of 64Cu-NODAGA-CANF up to 48 hours, Effective Dose of 64Cu-NODAGA-CANF up to 48 hours and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
64Cu-NODAGA-CANF
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT07800481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800481.